Company
Recce Pharmaceuticals Ltd
ASX:RCE
Recce Pharmaceuticals Ltd (ASX:RCE) is developing a new class of synthetic anti-infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
170 stories · page 2 of 2
The smart money in medicine: the silent pandemic
When antibiotics – which have underwritten our way of life for the last 100 years – are no longer effective, mundane medical procedures will become almost impossibly risky.
Recce Pharmaceuticals RECCE327 treatment ‘significantly’ reduces COVID-19 in hamsters
“The data received from Viroclinics indicates the potential of R327’s capabilities as a treatment for viral infections,” said CEO James Graham.
Recce Pharmaceuticals accelerates and expands clinical programs across portfolio
“With good safety and encouraging signs of efficacy, we look ahead to new indications that can best adapt to physician and patient needs. We have therefore established an ambitious development plan, aiming to get new anti-infective therapie
Recce Pharmaceuticals to deliver opening R&D address at World Anti-Microbial Resistance Congress
There has been a lack of innovation in new antibiotic drug development, with almost every antibiotic on the market based on scientific discoveries from more than 30 years ago.
Recce Pharmaceuticals appoints Dr John Prendergast as executive chair
“Bringing a depth of knowledge and well recognised capability as a veteran in biotechnology and international capital markets, we greatly look forward to his [Dr Prendergast's] continued contributions over the time ahead," CEO James Graham
Recce Pharmaceuticals appoints Alistair McKeough as non-executive director
Recce chairman Dr John Prendergast said: “He knows the company well, is excited about the future for Recce and brings deep insights into Australia’s financial, corporate and regulatory environments.”
Recce Pharmaceuticals doses anti-infective trial’s seventh cohort with no serious adverse effects
Recce 327 is allegedly the only clinical-stage new class of antibiotic in the world being developed for sepsis — the largest unmet medical need in human health.
Recce Pharmaceuticals appoints scientific adviser to fulltime position as it develops pipeline tackling antibiotic resistance
“I am delighted to join the Recce team and look forward to the time ahead in addressing the global health problem of antibiotic-resistant superbugs and emerging viral pathogens,” Dr Philip Sutton said.
ASX lifts after seven days, but recession fears loom as inflation gets worse
Treasurer Jim Chalmers says inflation will get worse before it gets better as RBA chair calms the waters over recession fears.
Recce Pharmaceuticals jumps on positive safety data during trial dosing participants with anti-infective
According to a global antibiotic pipeline review, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.
Recce Pharmaceuticals fields positive safety data from fifth cohort of phase 1 trial for synthetic anti-infective asset
“This data builds on previous cohorts and validates RECCE® 327’s compelling safety and tolerability profile, with the potential to serve as a solution for patients with sepsis,” says CEO James Graham.
Recce Pharmaceuticals progresses to 2,000mg dosing levels
James Graham, Chief Executive Officer of Recce Pharmaceuticals Ltd said, “Recommendation to commence ‘high dosing’ at 2,000mg – a 40-fold increase from initial dosing of 50mg in Cohort 1 by the independent safety committee is a welcome vali
Recce Pharmaceuticals granted anti-viral patent in Hong Kong for RECCE Anti-Infectives
“This newly granted patent by the Hong Kong Special Administrative Region of the People's Republic of China is another endorsement for our commercial and clinical development strategy highlighting the potential of our Australian anti-infect
Recce Pharmaceuticals dosing trial for next-generation antibiotic indicates good safety and tolerability
The company has recorded positive safety data from the fourth cohort of its Phase 1 clinical trial evaluating healthy participants intravenously dosed with anti-infective candidate RECCE® 327.
Recce Pharmaceuticals granted A$3 million boost for infectious disease R&D
Recce Pharmaceuticals CEO James Graham welcomes the rebate: “We appreciate the continued support and acknowledgement by the Australian Government for the critical work undertaken in our infectious disease programs. This non-dilutionary cash
Recce Pharmaceuticals sees safety committee clear next dose in Phase I Clinical Study of sepsis drug RECCE® 327
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.
Recce Pharmaceuticals doses final patients in third cohort of Phase 1 clinical trial evaluating IV RECCE® 327 in healthy subjects
“Completing this Cohort with the maximum number of subjects, sees R327 (500mg, I.V.) further a compelling Safety profile at a milestone dose. We anticipate recommendation to start dosing Cohort 4 at higher concentrations again in near weeks
Recce Pharmaceuticals demonstrates positive safety data from Phase I trial of sepsis drug RECCE® 327
According to PEW Charitable Trusts global antibiotic pipeline review, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.
Recce Pharmaceuticals reveals positive safety data from phase I clinical trial of RECCE 327
According to PEW Charitable Trusts global antibiotic pipeline review, RECCE 327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.
Recce Pharmaceuticals higher on positive safety data from first cohort of phase 1 clinical trial for RECCE® 327
According to PEW Charitable Trust, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.
Recce Pharmaceuticals recruits 10 healthy males for Phase 1 trials
R327 is administered as a single dose via a 1-hour IV infusion at a uniform rate, with all 80 subjects anticipated to have been dosed by the end of H1 2022.
Travel stocks fly the ASX higher… and what is happening on the crypto front this week
Speculation has been rife over what caused the flash crash, with some analysts citing the expiry of leveraged positions. Other evidence meanwhile points to significantly increased activity with investors moving crypto assets from wallets to
Recce Pharmaceuticals encouraged by ongoing Phase I/II clinical trial for burn wound infection treatment, shares up
“This initial update builds upon strong pre-clinical data demonstrating fast and efficient killing activity against common and problematic bacterial strains, and we are excited for the potential of R327 in the clinic," says CEO.
Recce Pharmaceuticals tapping European investor interest to accelerate anti-infective strategy
In March this year, Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
Recce Pharmaceuticals receives ethics approval to start Phase I Intravenous Clinical Trial of RECCE® 327
Receiving human ethics approval is a momentous achievement for Recce and the clinicians seeking effective treatments to combat antibiotic-resistant bacteria,” says chairman.
Recce Pharmaceuticals’ R327 demonstrates positive efficacy against ‘flesh-eating’ bacteria
RECCE® 327 (R327) has been shown to reduce deadly flesh-eating bacterial count below limit of quantification within 24 hours, at varying concentrations.
Recce Pharmaceuticals R327 progresses to stage 2 of SARS-CoV-2 Antiviral Screening Program at CSIRO
Following encouraging test results from stage1A and stage1B, RECCE® R327 received a qualified recommendation to advance to stage 2 of the program for further testing to be conducted by CSIRO.
Recce Pharmaceuticals buoyed by preliminary results from SARS-CoV-2 antiviral screening program
The company is pioneering the development and commercialisation of new classes of synthetic anti-infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.
Recce Pharmaceuticals to talk new class of synthetic antibiotics at Proactive’s CEO Sessions
Five companies will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.
Recce Pharmaceuticals to benefit from $5 million in government funds for AMR Research Hub
The company is pioneering the development of a new class of synthetic antibiotics with broad-spectrum activity, designed to address the problem of antibiotic superbugs.
Recce Pharmaceuticals attracts $1.8 million as it moves toward human clinical trials
The company’s lead candidate RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria.
Recce Pharmaceuticals a leading ASX gainer after receiving additional R&D tax incentive rebate
Overseas Advanced Drug Development expenditure for RECCE® 327 results in extra payment of $861,590.
Recce Pharmaceuticals to discuss synthetic antibiotics at Proactive's CEO Sessions
James Graham will discuss with investors the next key steps.
Reward Minerals brings Tier 1 sulphate of potash project to Proactive's CEO Sessions
Greg Cochran will discuss with investors the next key steps.
Recce to reveal submission details from FDA
The halt will remain in place until Thursday 16th November 2017.
Recce begins automated production of synthetic antibiotic
Recce 327 is a synthetic compound being developed to fight against superbugs.
Recce secures funding to fight antibiotic-resistant superbugs
Funding from New York-based asset manager, The Lind Partners.
Recce moves closer to clinical study application in the U.S.
Superbugs are widely acknowledged as a threat to human and animal health.
Recce continues to make progress against antibiotic-resistant superbugs
Intravenous infusion of Recce’s lead compound was well tolerated.
Recce’s compound shows promising results against superbugs
Recce (ASX:RCE) has received positive early results for its lead product candidate RECCE 327 as a potential treatment against drug resistant E. coli bacteria.
Recce’s anti-cancer compound appears to be well tolerated
Recce Ltd’s (ASX:RCE) share price has increased after receiving positive toxicology results from a dose escalation study of its lead compound RECCE 327, in a mouse with cancer.